Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 197 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Parexel Clear all

Conditions: Metastatic Prostate Cancer
Interventions: AZD0516, AZD9574; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Male only
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: Fayetteville, Arkansas • Los Angeles, California • Towson, Maryland + 8 more

Conditions: Asthma
Interventions: Albuterol dry powder inhaler, Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler); Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Lakewood, Colorado + 5 more

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: Synairgen Research Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Urinary Tract Infections
Interventions: LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX; Drug
Lead sponsor: Locus Biosciences; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Fresno, California • Lancaster, California • Los Angeles, California + 13 more

Conditions: Diabetic Foot Ulcers
Interventions: Antimicrobial Peptide PL-5 Topical Spray and Placebo; Drug
Lead sponsor: Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Vista, California • Miami, Florida • Tampa, Florida

Conditions: Healthy
Interventions: Rodatristat Ethyl 300 mg BID, Rodatristat Ethyl 600 mg BID, Placebo; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC /VI, UMEC, VI, FF; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Progressive Metastatic Castrate-Resistant Prostate Cancer
Interventions: AZD4635, Durvalumab, Cabazitaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Sacramento, California • Tampa, Florida • Atlanta, Georgia + 2 more

Conditions: Healthy
Interventions: Supratherapuetic dose of Nestorone, Placebo, Moxifloxacin; Drug
Lead sponsor: Population Council; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Participants
Interventions: AZD5004; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Immunologic Deficiency Syndromes
Interventions: GC5107; Biological
Lead sponsor: Green Cross Corporation; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 10
States / cities: Centennial, Colorado • North Palm Beach, Florida • Plymouth, Minnesota + 6 more

Conditions: BACTERIAL VAGINOSIS
Interventions: RIFAXIMIN VAGINAL TABLET 25 MG, RIFAXIMIN VAGINAL TABLET 100 MG, PLACEBO VAGINAL TABLET, METROGEL VAGINAL; Drug
Lead sponsor: Alfasigma S.p.A.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Solid Tumor
Interventions: Durvalumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 12
States / cities: Fullerton, California • Washington D.C., District of Columbia • Augusta, Georgia + 9 more

Conditions: Neurogenic Bladder, Non-Neurogenic Bladder
Interventions: Not listed
Lead sponsor: Hollister Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Libertyville, Illinois

Conditions: Renal Cell Carcinoma
Interventions: Tivozanib, Nivolumab; Drug
Lead sponsor: AVEO Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 36
States / cities: Duarte, California • Irvine, California • La Jolla, California + 31 more

Conditions: Healthy Volunteers
Interventions: AZD4831; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Obesity
Interventions: Petrelintide, Placebo; Drug
Lead sponsor: Zealand Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 19
States / cities: Birmingham, Alabama • Boca Raton, Florida • Clearwater, Florida + 16 more

Conditions: Healthy Volunteers - Male and Female
Interventions: KP-001, Moxifloxacin 400 mg, Placebo; Drug
Lead sponsor: Kaken Pharmaceutical; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteers
Interventions: AZD2373 subcutaneous injection, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Healthy Participants
Interventions: AZD5004, Itraconazole, EE/LNG; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Subjects
Interventions: KBP-7072, Placebo; Drug
Lead sponsor: KBP Biosciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Saquinavir, Nevirapine, Zidovudine, Zalcitabine; Drug
Lead sponsor: Parexel; Industry
Eligibility: 13 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Advanced Solid Tumours
Interventions: Adavosertib, Itraconazole, Rifampicin, Omeprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Portland, Oregon • Austin, Texas • Dallas, Texas

Conditions: Advanced Haematological Malignancies
Interventions: AZD4573, Acalabrutinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Duarte, California • La Jolla, California • Houston, Texas + 1 more

Search by objective public record fields.

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

Pilot Test of COVID-19 Related Clinical Outcome Assessment Methodology and Qualitative Evidence of Content Validity

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers

Multiple-Ascending Dose in Japanese Patients Bridging Study

A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers

A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis

Durvalumab Long-Term Safety and Efficacy Study

Continence Care Registry

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.

Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults

A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants

Study of KBP-7072 in Healthy Male and Female Subjects

The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection

A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer